Diabetes

The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

Doctor measuring patient's blood pressure | Image credit: Andrey Popov – stock.adobe.com
Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes

November 19th 2024

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.

Young man frustrated with finances | Image credit: master1305 – stock.adobe.com
Young Adults With Low Incomes Have Higher Diabetes Mortality Risk

November 14th 2024

Diabetes | Image credit: Minerva Studio - stock.adobe.com.jpg
Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers

November 13th 2024

AJMC Q&A with Dr Sanjula Jain | Background image credit: ipopba – stock.adobe.com
Rethinking Diabetes Care: Are New Therapies Adding Value or Cost?

November 5th 2024

Aerial shot of neighborhood | Image credit: trekandphoto – stock.adobe.com
How Neighborhood Social Needs Drive Diabetes Care Disparities

October 18th 2024

More News

Weight Management, Group Visits Help Patients With Diabetes Achieve Glycemic Control
November 9th 2019

Weight Management, Group Visits Help Patients With Diabetes Achieve Glycemic Control

Laura Joszt, MA
Patients with diabetes who participated in a program of group medical visits (GMVs) and intensive weight management showed improvements in glycemic control, according to a study published in JAMA Internal Medicine.
This Week in Managed Care: November 8, 2019
November 8th 2019

This Week in Managed Care: November 8, 2019

This week, the top managed care news included CMS started planning for life after the Oncology Care Model; a judge blocked a rule requiring immigrants to have health coverage; Election Day brought news for Medicaid work rules.
Site Logo
November 4th 2019

Final ICER Report Finds Empagliflozin More Cost Effective Than Oral Semaglutide for Type 2 Diabetes

Mary Caffrey
Oral semgalutide’s price, along with its potential for adverse events, caused ICER to give empagliflozin the edge in cost effectiveness as physicians and health plans evaluate which type 2 diabetes therapy should be given after metformin.
This Week in Managed Care: November 1, 2019
November 1st 2019

This Week in Managed Care: November 1, 2019

This week, the top managed care stories included a report from the FDA considering how to avoid drug shortages; a white paper finds rising comfort with telehealth even as use of digital health tools stagnates; data show a spike in the number of uninsured children.
Final Rule on New Kidney Care Model Seeks Reduced Spending on ESRD
November 1st 2019

Final Rule on New Kidney Care Model Seeks Reduced Spending on ESRD

Mary Caffrey
Rising rates of obesity and diabetes have raised concerns that more people could be headed for end-stage renal disease (ESRD); thus, Medicare has been seeking ways to reduce the cost of care and to improve the quality of life for people on dialysis. Scientists are focusing on whether more patients with early-stage type 2 diabetes should take sodium glucose co-transporter 2 inhibitors, which have been shown to slow renal decline.
Senators Ask CMS to Change Course on Virtual Medicare DPP
October 31st 2019

Senators Ask CMS to Change Course on Virtual Medicare DPP

Mary Caffrey
The 19 signers of the letter to HHS Secretary Alex Azar and CMS Administrator Seema Verma include Senate Finance Committee members and lawmakers from states with high rates of diabetes and obesity.
Podcast: This Week in Managed Care—GOP Releases Part of Its Healthcare Plan and Other Health News
October 27th 2019

Podcast: This Week in Managed Care—GOP Releases Part of Its Healthcare Plan and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
What We're Reading: Meth Overdoses Surge; Oklahoma Medicaid Campaign; FTC Sues for Diabetes Claims
October 25th 2019

What We're Reading: Meth Overdoses Surge; Oklahoma Medicaid Campaign; FTC Sues for Diabetes Claims

AJMC Staff
A CDC report said that, overall, fentanyl continues to drive drug overdose deaths, but in almost half of the country, methamphetamine is the leading killer; backers of Medicaid expansion in Oklahoma said they submitted more than enough signatures to get the measure on the ballot in 2020; the Federal Trade Commission is suing publishers of "The Doctor's Guide to Reversing Diabetes in 28 Days" on the grounds that they are falsely promising a cure without dietary changes or exercise and stating that those changes will make diabetes worse.
This Week in Managed Care: October 25, 2019
October 25th 2019

This Week in Managed Care: October 25, 2019

This week, the top managed care news included the average Affordable Care Act premiums falling 4%; the FDA approving a triple combination treatment for cystic fibrosis; House Republicans releasing part 1 of their healthcare plan.
Adding Empagliflozin to Insulin Cuts A1C in Type 1 Diabetes, Reduces CV Risk in Study
October 24th 2019

Adding Empagliflozin to Insulin Cuts A1C in Type 1 Diabetes, Reduces CV Risk in Study

Mary Caffrey
The advantage of empagliflozin, and the sodium glucose cotransporter 2 class generally, is that its unique mechanism expels excess glucose through the urine, thus offering the possibility of reducing glucose variability—eliminating the “roller coaster” effect that many with type 1 diabetes experience that can cause long-term microvascular damage.
Black Patients With Diabetes May Have Greater Hospital Readmission Risk, Study Finds
October 20th 2019

Black Patients With Diabetes May Have Greater Hospital Readmission Risk, Study Finds

Alison Rodriguez
Black patients with diabetes may have a significantly higher risk of readmission to hospitals than other ethnic and racial minorities due to the high burden and complications of the disease, according to research published in JAMA Network Open.
Abbott, Omada Health to Combine Digital Coaching With CGM for Those With Type 2 Diabetes
October 16th 2019

Abbott, Omada Health to Combine Digital Coaching With CGM for Those With Type 2 Diabetes

Mary Caffrey
Omada Health, a longtime leader in digital health coaching for diabetes prevention and type 2 diabetes (T2D) care, and Abbott, maker of the FreeStyle Libre, said the partnership will “create a new paradigm” in T2D management.
Empagliflozin Beats Pair of DPP-4s in Cost-Effectiveness for Patients With Type 2 Diabetes, CVD
October 14th 2019

Empagliflozin Beats Pair of DPP-4s in Cost-Effectiveness for Patients With Type 2 Diabetes, CVD

Mary Caffrey
The authors say their findings align with other analyses showing the cost-effectiveness of sodium glucose co-transporter 2 (SGLT2) inhibitors.
What We're Reading: Judge Denies Trump Immigration Proposal; Diabetes Risk Test Eyed; 29 Deaths Now Tied to Vaping
October 14th 2019

What We're Reading: Judge Denies Trump Immigration Proposal; Diabetes Risk Test Eyed; 29 Deaths Now Tied to Vaping

AJMC Staff
Federal judges denied a Trump administration proposal to deny green cards to immigrants requiring public benefits; researchers aim to develop a test to assess hereditary diabetes risk; vaping-related deaths rise to 29 nationwide.
What We're Reading: FDA Clears Dexcom G6 Pro CGM; Cleveland Clinic and Oscar Expand Health Plans; Planned Parenthood Election Spending
October 10th 2019

What We're Reading: FDA Clears Dexcom G6 Pro CGM; Cleveland Clinic and Oscar Expand Health Plans; Planned Parenthood Election Spending

AJMC Staff
FDA clears Dexcom G6 Pro CGM System for use among healthcare professionals; Cleveland Clinic and Oscar expand healthcare coverage to 3 additional Ohio counties; Planned Parenthood announces record-high election spend to support Democratic and pro-abortion candidates.
Next Chapter of Intarcia's Mini Pump for Diabetes Begins as FDA Accepts Resubmitted NDA
October 8th 2019

Next Chapter of Intarcia's Mini Pump for Diabetes Begins as FDA Accepts Resubmitted NDA

Mary Caffrey
More than 2 years after the FDA derailed the trajectory of its novel treatment system for type 2 diabetes (T2D), Intarcia Therapeutics today announced that regulators have accepted a resubmitted new drug application for the mini pump that delivers a continuous dose of exenatide.
Experimental Drug Reverses Fatty Liver Disease, Cuts Cholesterol
October 7th 2019

Experimental Drug Reverses Fatty Liver Disease, Cuts Cholesterol

Mary Caffrey
A study last year pointed to empagliflozin as the best choice for patients who have type 2 diabetes and non-alcoholic fatty liver disease.
Podcast: This Week in Managed Care—Hospital Readmission and Other Health News
October 6th 2019

Podcast: This Week in Managed Care—Hospital Readmission and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: October 4, 2019
October 4th 2019

This Week in Managed Care: October 4, 2019

This week, the top managed care news included Medicare cuts hospital payments over readmissions; a second-generation chimeric antigen receptor T-cell therapy shows promise; a diabetes drug is approved to prevent kidney failure for the first time.
FDA Approves Canagliflozin to Prevent Kidney Failure, Hospitalization for Heart Failure
October 1st 2019

FDA Approves Canagliflozin to Prevent Kidney Failure, Hospitalization for Heart Failure

Mary Caffrey
The new indication is based on results of the CREDENCE trial, which found that canagliflozin reduced the risk of renal failure or death by 30% in those that had both type 2 diabetes and diabetic kidney disease.
Podcast: This Week in Managed Care—State, Federal Crackdowns on Vaping, and Other Health News
September 29th 2019

Podcast: This Week in Managed Care—State, Federal Crackdowns on Vaping, and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Site Logo
September 27th 2019

Impact of Switching Analogue Insulin to Human Insulin in Diabetes

Kyunghwa Park, PharmD Angela Eng Jeong, PharmD Eric Guenther-Gleason, PharmD, MS Sachin H. Jain, MD, MBA
Converting from analogue insulin to human insulin is associated with a clinical insignificant increase in glycated hemoglobin of 0.16% but with improved insulin adherence.
Site Logo
September 27th 2019

Examining the Reality of What Insulin Costs Do to Patients

Robert A. Gabbay, MD, PhD, FACP
The editor-in-chief of Evidence-Based Diabetes Management™ introduces the special issue, Perspectives on Insulin Pricing, and shares that he has seen rationing among his own patients.
This Week in Managed Care: September 27, 2019
September 27th 2019

This Week in Managed Care: September 27, 2019

This week, the top managed care news included state and federal crackdowns on vaping that forced out the president of Juul; FDA approved a groundbreaking diabetes treatment; Medicare Advantage premiums will decline for 2020.
Site Logo
September 27th 2019

Biosimilar Insulin Could Offer Patients Cost-Saving Options

Sara Karlovitch
From the Center for Biosimilars®, a discussion on giving patients new, less expensive alternatives for managing diabetes.
Site Logo
September 27th 2019

How Prepared Is the United States for the Transition of Insulins to Regulation as Biologics?

Kelly Davio
From The Center for Biosimilars®, a discussion of a regulatory change coming in 2020: Insulins have always been biologics from a scientific perspective, and the products themselves will not change as a result of bringing them under regulation as biologics as a matter of law. However, labeling for these products will change.
Site Logo
September 26th 2019

Could Aiming Insulin at the Liver Be an Answer to Using Less?

Mary Caffrey
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
Site Logo
September 26th 2019

Gathering Evidence on Insulin Rationing: Answers and Future Questions

Mary Caffrey
The results of a study published last year from authors at Yale Diabetes Center suggest that rationing is more common than the healthcare system wants to admit. Senior author Kasia Lipska, MD, MHS, says the findings raise a whole new set of questions.
Site Logo
September 26th 2019

JDRF's Kowalski Sees Hope in Bipartisan Support for Insulin Pricing Reform

Andrew Smith
Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.
Site Logo
September 25th 2019

As a Child, Diabetes Was Hard to Accept. Now She's Living With the Complications

Jaime Rosenberg
The diagnosis of diabetes can be hard for a teenager to accept. Add insulin affordability to the mix, and by the time a young adult learns to live with the disease, the complications have already arrived.
<1
...
151617181920212223
...
97>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo